Is psoriatic arthritis a result of abnormalities in acquired or innate immunity?

Current Rheumatology Reports

Volumn 14, Issue 4, 2012, Pages 375-382

  Lories, Rik J ^a   De Vlam, Kurt ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Adaptive immunity; Ankylosis; Arthritis; Bone formation; Innate immunity; Osteoclasts; Psoriasis; Psoriatic arthritis

Indexed keywords

ADAPTIVE IMMUNITY; CLINICAL FEATURE; COMPLEX FORMATION; DENDRITIC CELL; DISEASE ASSOCIATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INNATE IMMUNITY; JOINT DESTRUCTION; NONHUMAN; OSSIFICATION; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; SIGNAL TRANSDUCTION; TISSUE REGENERATION;

ADAPTIVE IMMUNITY; ARTHRITIS, PSORIATIC; BONE REMODELING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNITY, INNATE; OSTEOGENESIS; PSORIASIS;

EID: 84864840246     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-012-0257-3     Document Type: Review

References (60)

1. Ibrahim G, Waxman R, Helliwell PS. The prevalence of psoriatic arthritis in people with psoriasis. Arthritis Rheum. 2009;61 (10):1373-8.
2. Gladman DD. Natural history of psoriatic arthritis. Bailliere's Clin Rheumatol. 1994;8(2):379-94.
3. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496-509.
4. Di Meglio P, Perera GK, Nestle FO. The multitasking organ: recent insights into skin immune function. Immunity. 2011;35 (6):857-69.
5. Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007;449(7162):564-9.
6. Ganguly D, Chamilos G, Lande R, et al. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med. 2009;206(9):1983-94.
7. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007;8(9):950-7.
8. Ma HL, Liang S, Li J, et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest. 2008;118(2):597-607.
9. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3(1):55-78.
10. Nash P, Mease PJ, Braun J, van der Heijde D. Seronegative spondyloarthropathies: to lump or split? Annals Rheum Dis. 2005;64 Suppl 2:ii9-13.
11. Dougados M. Psoriatic arthritis: is it for real? Joint Bone Spine. 2007;74(4):311-2.
12. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet. 2009;373(9664):659-72.
13. Tan AL, McGonagle D. Psoriatic arthritis: correlation between imaging and pathology. Joint Bone Spine. 2010;77(3):206-11.
14. McGonagle D, Lories RJ, Tan AL, Benjamin M. The concept of a "synovio-entheseal complex" and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum. 2007;56(8):2482-91.
15. Lories R. The balance of tissue repair and remodeling in chronic arthritis. Nat Rev Rheumatol. 2011;7(12):700-7.
16. Pattison E, Harrison BJ, Griffiths CE, et al. Environmental risk factors for the development of psoriatic arthritis: results from a case-control study. Ann Rheum Dis. 2008;67(5):672-6.
17. Kamradt T, Schubert D. The role and clinical implications of G6PI in experimental models of rheumatoid arthritis. Arthritis Res Ther. 2005;7(1):20-8.
18. Armaka M, Apostolaki M, Jacques P, et al. Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J Exp Med. 2008;205 (2):331-7.
19. McGonagle D. Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease. J Eur Acad Dermatol Venereol. 2009;23 Suppl 1:9-13.
20. Tan AL, Benjamin M, Toumi H, et al. The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis-a high-resolution MRI and histological study. Rheumatology (Oxford). 2007;46(2):253-6.
21. Lande R, Giacomini E, Serafini B, et al. Characterization and recruitment of plasmacytoid dendritic cells in synovial fluid and tissue of patients with chronic inflammatory arthritis. J Immunol. 2004;173(4):2815-24.
22. Jongbloed SL, Lebre MC, Fraser AR, et al. Enumeration and pheno-typical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis. Arthritis Res Ther. 2006;8(1):R15.
23. Wenink MH, Santegoets KC, Butcher J, et al. Impaired dendritic cell proinflammatory cytokine production in psoriatic arthritis. Arthritis Rheum. 2011;63(11):3313-22.
24. Rambukkana A, Das PK, Witkamp L, et al. Antibodies to mycobacterial 65-kDa heat shock protein and other immunodominant antigens in patients with psoriasis. J Investig Dermatol. 1993;100 (1):87-92.
25. Jandus C, Bioley G, Rivals JP, et al. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum. 2008;58(8):2307-17.
26. Leipe J, Grunke M, Dechant C, et al. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum. 2010;62(10):2876-85.
27. Yeremenko N, Baeten D. IL-17 in spondylarthritis: is the T-party over? Arthritis Res Ther. 2011;13(3):115.
28. Noordenbos T, Yeremenko N, Gofita I, et al. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum. 2012;64(1):99-109.
29. Glatigny S, Fert I, Blaton MA, et al. Proinflammatory Th17 cells are expanded and induced by dendritic cells in spondylarthritis-prone HLA-B27-transgenic rats. Arthritis Rheum. 2012;64 (1):110-20.
30. Canete JD, Martinez SE, Farres J, et al. Differential Th1/Th2 cyto-kine patterns in chronic arthritis: interferon gamma is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies. Ann Rheum Dis. 2000;59(4):263-8.
31. Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum. 2011;63(4):939-48.
32. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373(9664):633- 40.
33. Strober BE, Crowley JJ, Yamauchi PS, et al. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol. 2011;165(3):661-8.
34. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68 (9):1387-94.
35. Vandooren B, Noordenbos T, Ambarus C, et al. Absence of a classically activated macrophage cytokine signature in peripheral spondylarthritis, including psoriatic arthritis. Arthritis Rheum. 2009;60(4):966-75.
36. Kruithof E, Baeten D, De Rycke L, et al. Synovial histopathology of psoriatic arthritis, both oligo-and polyarticular, resembles spon-dyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther. 2005;7(3):R569-80.
37. Lories RJ, Baeten DL. Differences in pathophysiology between rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheu-matol. 2009;27(4 Suppl 55):S10-4.
38. Lories RJ. Joint homeostasis, restoration, and remodeling in oste-oarthritis. Best Pract Res Clin Rheumat. 2008;22(2):209-20.
39. Siannis F, Farewell VT, Cook RJ, et al. Clinical and radiological damage in psoriatic arthritis. Ann Rheum Dis. 2006;65(4):478-81.
40. van der Heijde D, Kavanaugh A, Gladman DD, et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum. 2007;56(8):2698-707.
41. van Kuijk AW, DeGroot J, Koeman RC, et al. Soluble biomarkers of cartilage and bone metabolism in early proof of concept trials in psoriatic arthritis: effects of adalimumab versus placebo. PloS one. 2010, 5(9).
42. Schett G, David JP. The multiple faces of autoimmune-mediated bone loss. Nat Rev Endocrinol. 2010;6(12):698-706.
43. Xiong J, Onal M, Jilka RL, et al. Matrix-embedded cells control osteoclast formation. Nat Med. 2011;17(10):1235-41.
44. Nakashima T, Hayashi M, Fukunaga T, et al. Evidence for osteo-cyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011;17(10):1231-4.
45. Okamoto K, Takayanagi H. Osteoclasts in arthritis and Th17 cell development. Int Immunopharmacol. 2011;11(5):543-8.
46. Pollinger B, Junt T, Metzler B, et al. Th17 cells, not IL-17+ gammadelta T cells, drive arthritic bone destruction in mice and humans. J Immunol. 2011;186(4):2602-12.
47. Ritchlin CT, Haas-Smith SA, Li P, et al. Mechanisms of TNF-alpha-and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest. 2003;111(6):821-31.
48. Colucci S, Brunetti G, Cantatore FP, et al. Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFalpha, and IL-7 in an in vitro model derived from human psoriatic arthritis. J Pathol. 2007;212(1):47-55.
49. Chiu YG, Shao T, Feng C, et al. CD16 (FcRgammaIII) as a potential marker of osteoclast precursors in psoriatic arthritis. Arthritis Res Ther. 2010;12(1):R14.
50. Vandooren B, Cantaert T, Noordenbos T, et al. The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation. Arthritis Rheum. 2008;58(3):718-29.
51. Lories RJ, Luyten FP, de Vlam K. Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis. Arthritis Res Ther. 2009;11(2):221.
52. Maksymowych WP. Disease modification in ankylosing spondyli-tis. Nat Rev Rheumatol. 2010;6(2):75-81.
53. Lories RJ, Derese I, Ceuppens JL, Luyten FP. Bone morphogenetic proteins 2 and 6, expressed in arthritic synovium, are regulated by proinflammatory cytokines and differentially modulate fibroblast-like synoviocyte apoptosis. Arthritis Rheum. 2003;48(10):2807-18.
54. Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med. 2007;13(2):156-63.
55. Lories RJ, Derese I, de Bari C, Luyten FP. Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis Rheum. 2007;56(2):489-97.
56. Eder L, Chandran V, Gladman DD. Repair of radiographic joint damage following treatment with etanercept in psoriatic arthritis is demonstrable by 3 radiographic methods. J Rheumatol. 2011;38 (6):1066-70.
57. O'Rielly DD, Rahman P. Genetics of susceptibility and treatment response in psoriatic arthritis. Nat Rev Rheumatol. 2011;7 (12):718-32.
58. Sonder SU, Saret S, Tang W, et al. IL-17-induced NF-kappaB activation via CIKS/Act1: physiologic significance and signaling mechanisms. J Biol Chem. 2011;286(15):12881-90.
59. Bowes J, Eyre S, Flynn E, et al. Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris. Ann Rheum Dis. 2011;70(6):1016-9.
60. Eder L, Chandran V, Pellett F, et al. IL13 gene polymorphism is a marker for psoriatic arthritis among psoriasis patients. Ann Rheum Dis. 2011;70(9):1594-8.